Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/POR_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/POR_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/POR_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/POR_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/POR_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/POR_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000647314 | Skin | cSCC | protein acetylation | 84/4864 | 201/18723 | 6.94e-07 | 1.29e-05 | 84 |
GO:001604925 | Skin | cSCC | cell growth | 173/4864 | 482/18723 | 7.21e-07 | 1.34e-05 | 173 |
GO:001839414 | Skin | cSCC | peptidyl-lysine acetylation | 72/4864 | 169/18723 | 1.81e-06 | 3.02e-05 | 72 |
GO:004343426 | Skin | cSCC | response to peptide hormone | 150/4864 | 414/18723 | 2.11e-06 | 3.43e-05 | 150 |
GO:004206029 | Skin | cSCC | wound healing | 152/4864 | 422/18723 | 2.66e-06 | 4.26e-05 | 152 |
GO:001820515 | Skin | cSCC | peptidyl-lysine modification | 137/4864 | 376/18723 | 4.09e-06 | 6.09e-05 | 137 |
GO:004354314 | Skin | cSCC | protein acylation | 95/4864 | 243/18723 | 4.56e-06 | 6.71e-05 | 95 |
GO:004586128 | Skin | cSCC | negative regulation of proteolysis | 128/4864 | 351/18723 | 7.95e-06 | 1.09e-04 | 128 |
GO:2000117111 | Skin | cSCC | negative regulation of cysteine-type endopeptidase activity | 41/4864 | 86/18723 | 1.20e-05 | 1.53e-04 | 41 |
GO:0043154111 | Skin | cSCC | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 38/4864 | 78/18723 | 1.33e-05 | 1.67e-04 | 38 |
GO:000647514 | Skin | cSCC | internal protein amino acid acetylation | 66/4864 | 160/18723 | 1.72e-05 | 2.07e-04 | 66 |
GO:001839314 | Skin | cSCC | internal peptidyl-lysine acetylation | 65/4864 | 158/18723 | 2.19e-05 | 2.54e-04 | 65 |
GO:00065758 | Skin | cSCC | cellular modified amino acid metabolic process | 73/4864 | 188/18723 | 7.11e-05 | 6.85e-04 | 73 |
GO:003166728 | Skin | cSCC | response to nutrient levels | 160/4864 | 474/18723 | 8.44e-05 | 8.02e-04 | 160 |
GO:007137518 | Skin | cSCC | cellular response to peptide hormone stimulus | 104/4864 | 290/18723 | 1.15e-04 | 1.06e-03 | 104 |
GO:005134627 | Skin | cSCC | negative regulation of hydrolase activity | 130/4864 | 379/18723 | 1.74e-04 | 1.49e-03 | 130 |
GO:1901653110 | Skin | cSCC | cellular response to peptide | 124/4864 | 359/18723 | 1.75e-04 | 1.49e-03 | 124 |
GO:000975518 | Skin | cSCC | hormone-mediated signaling pathway | 72/4864 | 190/18723 | 1.92e-04 | 1.61e-03 | 72 |
GO:000155824 | Skin | cSCC | regulation of cell growth | 140/4864 | 414/18723 | 2.07e-04 | 1.72e-03 | 140 |
GO:0032869110 | Skin | cSCC | cellular response to insulin stimulus | 75/4864 | 203/18723 | 3.53e-04 | 2.78e-03 | 75 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
POR | SNV | Missense_Mutation | | c.1987G>A | p.Asp663Asn | p.D663N | P16435 | protein_coding | tolerated(0.23) | benign(0.009) | TCGA-A2-A0CL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
POR | SNV | Missense_Mutation | rs781866008 | c.838N>A | p.Asp280Asn | p.D280N | P16435 | protein_coding | deleterious(0.03) | benign(0.41) | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
POR | SNV | Missense_Mutation | rs782053091 | c.709N>A | p.Glu237Lys | p.E237K | P16435 | protein_coding | deleterious(0.05) | benign(0.182) | TCGA-BH-A0AU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
POR | SNV | Missense_Mutation | novel | c.893N>A | p.Gly298Glu | p.G298E | P16435 | protein_coding | deleterious(0.01) | benign(0.376) | TCGA-GM-A3NY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
POR | insertion | Frame_Shift_Ins | novel | c.937_938insG | p.Ser313CysfsTer6 | p.S313Cfs*6 | P16435 | protein_coding | | | TCGA-A8-A0A4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR |
POR | insertion | Nonsense_Mutation | novel | c.938_939insTTGAACCTGGGAGG | p.Lys314Ter | p.K314* | P16435 | protein_coding | | | TCGA-A8-A0A4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR |
POR | deletion | Frame_Shift_Del | novel | c.1514_1524delAGAACGGCGGC | p.Glu505AlafsTer66 | p.E505Afs*66 | P16435 | protein_coding | | | TCGA-AC-A8OQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
POR | deletion | In_Frame_Del | | c.443_445delNNN | p.Thr149del | p.T149del | P16435 | protein_coding | | | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR |
POR | SNV | Missense_Mutation | rs367782552 | c.773C>T | p.Ala258Val | p.A258V | P16435 | protein_coding | tolerated(0.29) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
POR | SNV | Missense_Mutation | novel | c.1897N>T | p.Gly633Trp | p.G633W | P16435 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-VS-A9U6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5447 | POR | ENZYME, DRUGGABLE GENOME | | sirolimus | SIROLIMUS | 23974086 |
5447 | POR | ENZYME, DRUGGABLE GENOME | | midazolam | MIDAZOLAM | 23324807,19801957 |
5447 | POR | ENZYME, DRUGGABLE GENOME | | cyclosporine | CYCLOSPORINE | 29135906,24658827,24061445 |
5447 | POR | ENZYME, DRUGGABLE GENOME | | zidovudine | ZIDOVUDINE | 22960662 |
5447 | POR | ENZYME, DRUGGABLE GENOME | | atorvastatin | ATORVASTATIN | 25521355 |
5447 | POR | ENZYME, DRUGGABLE GENOME | | nicotine | NICOTINE | |
5447 | POR | ENZYME, DRUGGABLE GENOME | | tacrolimus | TACROLIMUS | 23097010,25322286,26829596,30323313,24113216,26227094,21770725,24921414,24739669,25271728,24061445,28094348,29878980,29399716 |
5447 | POR | ENZYME, DRUGGABLE GENOME | | sunitinib | SUNITINIB | 28117434 |